Humira (adalimumab) is a medicine used to reduce inflammation and treat a variety of autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and juvenile idiopathic arthritis. It is an injectable biologic medicine that works by blocking an enzyme that helps regulate the body’s immune system and reduces inflammation.
Humira is the world’s top-selling drug and has been in use since 2003. It was developed by AbbVie Inc. and is the top-selling product of this company. In 2019, Humira had sales of $18.3 billion globally, making it one of the top five drugs in terms of revenue in the world.
In India, Humira is approved to treat rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis.
The global Humira market was valued at US$ 17070 million in 2022 and is anticipated to reach US$ 9235.6 million by 2029, witnessing a CAGR of -8.3% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
A detailed market research report on Global Humira Market available at: https://www.themarketreports.com/report/global-humira-market-research-report
This report aims to provide a comprehensive presentation of the global market for Humira, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Humira.
Market competition will intense. AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen and Boehringer Ingelheim are the key manufacturters of Humira. AbbVie is the leader of this industry by 97% market shares.
Ask for more details or sample of this report at: https://www.themarketreports.com/report/ask-your-query/1409610
The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479